Division of NeoGenomics Inc.
Latest From Clarient Inc.
At $1.2 billion, Q4 device financing was the second-lowest quarter of 2015; M&A dollar volume was also low, but included multiple deals across various cardiovascular markets. Diagnostics financing was also down in Q4, totaling $403 million; acquisitions were worth $441 million.
BMS replaced and signed a new deal with Five Prime Therapeutics in immuno-oncology; there was more consolidation in the pharma services industry with Walgreens' $17.2 billion acquisition of Rite Aid. Biopharma financing in October was down from the previous month to $2.1 billion; device fundraising also decreased, to $468 million.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced October 2015.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced September-October 2015.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Laboratory Testing Services
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- ChromaVision Medical Systems Inc.
- North America
- Parent & Subsidiaries
- NeoGenomics Inc.
- Senior Management
Cindy Collins, CEO
Renika Sehgal, CFO
Kenneth J Bloom, MD, CMO
- Contact Info
Phone: (949) 425-5700
Aliso Viejo, CA 92656
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.